Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which includes aberrant mucocutaneous pigmentation, and somatic LKB1 mutations occur in 10% of cutaneous melanoma. By somatically inactivating Lkb1 with K-Ras activation (±p53 loss) in murine melanocytes, we observed variably pigmented and highly metastatic melanoma with 100% penetrance. LKB1 deficiency resulted in increased phosphorylation of the SRC family kinase (SFK) YES, increased expression of WNT target genes, and expansion of a CD24+ cell population, which showed increased metastatic behavior in vitro and in vivo relative to isogenic CD24− cells. These results suggest that LKB1 inactivation in the context of RAS activation facilitates metastasis...
The STK11/LKB1 is a tumor suppressor involved in metabolism and cell motility. In BRAF$^{V600E}$ mel...
Three phenotypically related genetic syndromes and their lesions (LKB1, PTEN, and TSC1/2) are identi...
Loss of p16INK4a–RB and ARF–p53 tumor suppressor pathways, as well as activation of RAS–RAF signalin...
Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which inclu...
SummaryGermline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), whic...
Germline mutations in the LKB1/STK11 gene cause characteristic hamartomas and freckling to develop i...
For melanoma patients with metastatic, NRAS-mutant tumors, treatment options are limited. However, t...
Germline mutations in the LKB1/STK11 gene cause characteristic hamartomas and freckling to develop i...
Somatic inactivation of the serine/threonine kinase gene STK11/LKB1/PAR-4 occurs in a variety of can...
Germline mutations in the LKB1/STK11 gene cause characteristic hamartomas and freckling to develop i...
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. ...
Background: Understanding the biochemical mechanisms contributing to melanoma development and progre...
BACKGROUND: Understanding the biochemical mechanisms contributing to melanoma development and progre...
The serine/threonine kinase 11 (STK11/LKB1) is a tumor suppressor involved in metabolism and cell mo...
Peutz-Jeghers syndrome (PJS) is caused by germline mutations in the LKB1 gene, which encodes a serin...
The STK11/LKB1 is a tumor suppressor involved in metabolism and cell motility. In BRAF$^{V600E}$ mel...
Three phenotypically related genetic syndromes and their lesions (LKB1, PTEN, and TSC1/2) are identi...
Loss of p16INK4a–RB and ARF–p53 tumor suppressor pathways, as well as activation of RAS–RAF signalin...
Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which inclu...
SummaryGermline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), whic...
Germline mutations in the LKB1/STK11 gene cause characteristic hamartomas and freckling to develop i...
For melanoma patients with metastatic, NRAS-mutant tumors, treatment options are limited. However, t...
Germline mutations in the LKB1/STK11 gene cause characteristic hamartomas and freckling to develop i...
Somatic inactivation of the serine/threonine kinase gene STK11/LKB1/PAR-4 occurs in a variety of can...
Germline mutations in the LKB1/STK11 gene cause characteristic hamartomas and freckling to develop i...
Elucidating the contribution of somatic mutations to cancer is essential for personalized medicine. ...
Background: Understanding the biochemical mechanisms contributing to melanoma development and progre...
BACKGROUND: Understanding the biochemical mechanisms contributing to melanoma development and progre...
The serine/threonine kinase 11 (STK11/LKB1) is a tumor suppressor involved in metabolism and cell mo...
Peutz-Jeghers syndrome (PJS) is caused by germline mutations in the LKB1 gene, which encodes a serin...
The STK11/LKB1 is a tumor suppressor involved in metabolism and cell motility. In BRAF$^{V600E}$ mel...
Three phenotypically related genetic syndromes and their lesions (LKB1, PTEN, and TSC1/2) are identi...
Loss of p16INK4a–RB and ARF–p53 tumor suppressor pathways, as well as activation of RAS–RAF signalin...